Category, % | |
---|---|
Female, % (ratio) | 86.7 (26/30) |
Median age, yrs (IQR) | 43.5 (21) |
Ethnicity, % (ratio) | |
Caucasian | 73.3 (22/30) |
Asian | 13.3 (4/30) |
Pacific Islander | 3.3 (1/30) |
Hispanic/Latino | 3.3 (1/30) |
Black/African American | 3.3 (1/30) |
More than 1 ethnicity | 3.3 (1/30) |
ACR criteria, % (ratio) | |
Subjects with 3/7 criteria | 40 (12/30) |
Subjects with 4/7 criteria | 40 (12/30) |
Subjects with ≥ 5/7 criteria | 20 (6/30) |
Median duration of symptoms, wks (IQR), % | 13 (14) |
With RF, % (ratio) | 38 (11/29) |
With anti-CCP, % (ratio) | 21 (6/29) |
Median MHAQ* (IQR) | 0.13 (0.375) |
Median DAS28** (IQR) | 3.6 (1.67) |
IQR: interquartile range; ACR: American College of Rheumatology; RF: rheumatoid factor; anti-CCP: anti-cyclic citrullinated peptide antibodies.
↵* Modified Health Assessment Questionnaire (MHAQ) scored 0–3 (mild functional loss ≤ 0.375).
↵** Disease Activity Score (DAS28) scored 0–10 (> 5.1 = high disease activity; < 3.2 = low disease activity; < 2.6 = remission).